GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
James Porter, Nuvalent CEO
June 9, 2026 02:39 AM EDTUpdated 03:00 AM
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines due for FDA approval …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK to buy US lung cancer drug specialist Nuvalent for £8bn
GSK buys US biopharma company Nuvalent for $10.6B
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
GSK compra Nuvalent por US$ 10,6 bilhões e amplia aposta em oncologia
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma…
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. |…
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
The acquisition is thought to be GSK’s biggest deal in more than a decade.
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40%…
